Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2013 - 2026)

Grown Rogue International's (GRUSF) quarterly Income from Non-Controlling Interests came in at -$488826.0 in Q1 2026, down 239.26% year-on-year from $351029.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$321.7 billion in Q4 2025.

Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends

Grown Rogue International's Income from Non-Controlling Interests history runs 11 years deep, the most recent figure standing at -$488826.0 for Q1 2026.

  • On a quarterly basis, Income from Non-Controlling Interests fell 239.26% year-over-year to -$488826.0 in Q1 2026; TTM through Mar 2026 was -$182.1 billion, a 29.91% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 million, down 8499.04% from the prior year.
  • Income from Non-Controlling Interests rose to -$488826.0 in Q1 2026 per GRUSF's latest filing, from -$321.7 billion in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $139.6 billion in Q3 2025 and bottomed at -$321.7 billion in Q4 2025.
  • The 5-year median for Income from Non-Controlling Interests is $30728.0 (2024), against an average of -$21.5 billion.
  • Across the five-year window, Income from Non-Controlling Interests surged 11432.01% in 2022 and plunged 915246434.11% in 2024, its largest moves.
  • Year by year, Income from Non-Controlling Interests stood at $564607.0 in 2022, then tumbled by 94.76% to $29607.0 in 2023, then plunged by 915246434.11% to -$271.0 billion in 2024, then retreated by 18.72% to -$321.7 billion in 2025, then jumped by 100.0% to -$488826.0 in 2026.
  • Per Business Quant, the three latest GRUSF Income from Non-Controlling Interests figures stand at -$488826.0 (Q1 2026), -$321.7 billion (Q4 2025), and $139.6 billion (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Haleon 89.69 Bn 87.82 Bn - -
2 Teva Pharmaceutical Industries 35.84 Bn 32.10 Bn 1.97 Bn -
3 Zoetis 32.67 Bn 30.73 Bn 1.62 Bn -
4 Takeda Pharmaceutical 27.69 Bn 23.63 Bn 4.39 Bn 395,346.10
5 United Therapeutics 23.12 Bn 20.97 Bn 648.10 Mn -
6 RedHill Biopharma 21.80 Bn 21.80 Bn - -
7 Viatris 20.24 Bn 18.44 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.83 Bn 16.51 Bn 800.70 Mn -12.70 Mn
9 Elanco Animal Health 12.64 Bn 12.22 Bn 785.00 Mn -
10 Grown Rogue International 99.97 Mn 86.26 Mn 3.96 Mn -488,826.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -488,826.00
Dec 31, 2025 -321.70 Bn
Sep 30, 2025 139.57 Bn
Jun 30, 2025 99,131.00
Mar 31, 2025 -144,088.00
Dec 31, 2024 -270.98 Bn
Sep 30, 2024 130.78 Bn
Jun 30, 2024 80,039.42
Mar 31, 2024 30,728.00
Dec 31, 2023 29,607.00
Oct 31, 2023 210,129.00
Jul 31, 2023 119,093.00
Apr 30, 2023 -867.00
Jan 31, 2023 -339,408.00
Jan 31, 2022 564,607.00
Oct 31, 2021 1.12 Mn
Jul 31, 2021 283,126.00
Apr 30, 2021 -15,306.00
Jan 31, 2021 4,896.00
Oct 31, 2020 -38,608.00